Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11222801rdf:typepubmed:Citationlld:pubmed
pubmed-article:11222801lifeskim:mentionsumls-concept:C0007787lld:lifeskim
pubmed-article:11222801lifeskim:mentionsumls-concept:C0360714lld:lifeskim
pubmed-article:11222801lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:11222801lifeskim:mentionsumls-concept:C0450442lld:lifeskim
pubmed-article:11222801lifeskim:mentionsumls-concept:C0301625lld:lifeskim
pubmed-article:11222801pubmed:issue4lld:pubmed
pubmed-article:11222801pubmed:dateCreated2001-3-6lld:pubmed
pubmed-article:11222801pubmed:abstractTextRecent studies of hydroxy-methylglutaryl coenzyme A reductase inhibitors have demonstrated that therapy with statins is associated with a significant decrease in the risk of stroke and TIA in patients with coronary artery disease. The underlying mechanism responsible for this effect is unclear. The author presents two patients who had cessation of TIAs upon institution of statin therapy. A variety of non-lipid-lowering mechanisms may account for this beneficial effect. This initial observation, if confirmed by further study, may suggest a role for statin agents in preventing recurrent TIAs.lld:pubmed
pubmed-article:11222801pubmed:languageenglld:pubmed
pubmed-article:11222801pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11222801pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11222801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11222801pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11222801pubmed:statusMEDLINElld:pubmed
pubmed-article:11222801pubmed:monthFeblld:pubmed
pubmed-article:11222801pubmed:issn0028-3878lld:pubmed
pubmed-article:11222801pubmed:authorpubmed-author:AlbertsM JMJlld:pubmed
pubmed-article:11222801pubmed:issnTypePrintlld:pubmed
pubmed-article:11222801pubmed:day27lld:pubmed
pubmed-article:11222801pubmed:volume56lld:pubmed
pubmed-article:11222801pubmed:ownerNLMlld:pubmed
pubmed-article:11222801pubmed:authorsCompleteYlld:pubmed
pubmed-article:11222801pubmed:pagination531-2lld:pubmed
pubmed-article:11222801pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:meshHeadingpubmed-meshheading:11222801...lld:pubmed
pubmed-article:11222801pubmed:year2001lld:pubmed
pubmed-article:11222801pubmed:articleTitleSuppression of recurrent transient ischemic attacks by a statin agent.lld:pubmed
pubmed-article:11222801pubmed:affiliationStroke Acute Care Unit, Duke University Medical Center, Durham, NC, USA.lld:pubmed
pubmed-article:11222801pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11222801pubmed:publicationTypeCase Reportslld:pubmed